News Detail
New Delhi, 8 July 2024: The Multidisciplinary Committee of Experts (MDC), which advices the National Pharmaceutical Pricing Authority (NPPA), will be seeking clarity from the central drug regulator on the licensing requirement of a drug device combination of Cipla in order to det......
View Details
Source : Pharmabiz
Multidisciplinary Committee of Experts
MDC
NPPA
central drug regulator
drug device combination
Cipla
Ciphaler
inhaler device
dry powder inhaler
DPI
formoterol fumarate
budesonide
Turbuhaler
AstraZeneca
CDSCO
Synchro breath inhaler device
Related News
- UK regulator probes anti-depressants safety alerts after suicide link (12-12-2024)
- Haryana Food Department to Crack Down on Fake Protein Supplements After Major Bust (12-12-2024)
- Drug inspector sentenced to 3-yr rigorous imprisonment (12-12-2024)
- 11.12 crore worth of short-shelf life medicines expired due to delayed supply to TNMSC: CAG Report (12-12-2024)
- Ayush Ministry amends D&C Act to add Homoeopathy, Sowa Rigpa books and Pharmacopoeias (12-12-2024)
- Construction of all three bulk drug parks are in progress: Ministry of chemicals (12-12-2024)
- Four-member gang nabbed for selling ‘Mephentermine Sulphate’ injections in Hyderabad (12-12-2024)
- Combining BCL-2 and BTK inhibitors shows promise in chronic lymphocytic leukemia (CLL) (11-12-2024)
- Punjab cop arrests man for narcotic drugs case, gets fined by court (11-12-2024)
- NPPA Mandates Transparency in Angioplasty Billing with Separate Costs for Non-Stent Components: MoS Anupriya Patel (11-12-2024)